Expression of Ley antigen in human immunodeficiency virus-infected human T cell lines and in peripheral lymphocytes of patients with acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC) by unknown
EXPRESSION OF LeY ANTIGEN IN HUMAN
IMMUNODEFICIENCY VIRUS-INFECTED HUMAN T CELL
LINES AND IN PERIPHERAL LYMPHOCYTES OF PATIENTS
WITH ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS)
AND AIDS-RELATED COMPLEX (ARC)
BY MASAKAZU ADACHI," MASANORI HAYAMI,§
NOBUHITO KASHIWAGI,* TOSHINOBU MIZUTA,* YOSHIHIRO OHTA,§
MICHAEL JOHN GILL,11 DAVID S. MATHESON,' TAIKI TAMAOKI,**
CHIAKI SHIOZAWA,*,** AND SEN-ITIROH HAKOMORIU
From the *Japan Immunoresearch Laboratories, Takasaki 370; the *Department of
Immunological Research, Otsuka Pharmaceutical, Tokushima 771; the §Institute ofMedical
Science, University of Tokyo, Minato-ku, Tokyo 108, Japan; the °Departments ofMedical
Microbiology and Infectious Disease and Medicine, 'Department of Paediatrics and Internal
Medicine, and the "Department ofMedical Biochemistry, University of Calgary, Calgary,
Alberta T2N 4N1, Canada; and **The Biomembrane Institute, Departments ofPathobiology,
Microbiology, and Immunology, University of Washington, Seattle, Washington 98119
Acquired immune deficiency syndrome (AIDS) is recognized as a distinct new
disease whose etiology has been identified as being associated with infection of a
new class of lymphotrophic retrovirus termed human immunodeficiency virus
(HIV) (1, 2).' The disease is characterized by a disorder associated with an
impaired cell-mediated immunity and absolute lymphopenia, particularly re-
duced helper T lymphocytes (T4' or CD4). This is due to the fact that HIV
preferentially infects the CD4 lymphocyte population. AIDS may be preceded
by a presyndrome that is usually manifested by a complex of designated clinical
features and helper T lymphopenia (3-5). The presyndrome is called AIDS-
related complex (ARC) .' Diagnosis of infection with HIV is usually made on the
basis of detecting antibodies directed against HIV. The exact antibody profile
may vary with the stage of the disease (1). Despite significant progress in
understanding the pathogenesis of HIV, no studies have been performed regard-
ing carbohydrate antigens in T lymphoid cells infected with HIV, although
carbohydrate changes associated with functional change of cellular phenotypes
have been well documented (6). In this note, we present evidence that LeY
' Previously called, in various terms, human T cell lymphotropic virus III (HTLV-III), human
lymphadenopathy-associated virus (LAV), or AIDS-related virus (ARV) (reviewed in references 1,
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TABLE I
mAbs* Used in this Study and the Structures Defined by Them
lished data T
(Fu ca 1)
* All hydridomas secreting these antibodies were originally selected and established as being directed to tumor-associated antigens strongly
expressed in various human cancer cell lines or human cancer tissues.
$ A subclone ofa hybridonta originally described as AH6 (14).
determinant is highly expressed at the surface of human T cell lines only after
infection with HIV, as well as in T lymphocytes of peripheral blood of patients
with AIDS and ARC but not in normal lymphocytes of healthy individuals.
Materials and Methods
Cells and Viruses.
￿
Two human T cell leukemia lines, H-9 (7) and TALL-1 (8), used in
this experiment were originally isolated from T cell leukemia patients as previously
described. These cells were cultured in RPMI 1640 supplemented with 10% heat-
inactivated FCS containing 50 kg/ml of gentamycin. The cell population density of the
culture was maintained within 105-106/ml and subcultured every 3 d. Human T cell
lymphotropic virus III (HTLV-III) of HIV was isolated and characterized as previously
described (1, 7) and was maintained in TALL-1 cells in the laboratory of M. Hayami .
Method ofHIV Infection.
￿
A cell suspension of H-9 and TALL-1 cells at a cell population
density of 3 X 105/ml was mixed with 2 ml of culture supernatant containing HIV having
reverse transcriptase activity of 6-30 X 10" cpm/ml in the presence of 1 ug/ml Polybrene
(Sigma Chemical Co., St. Louis, MO) and subcultured every 3 d. Infection of HIV was
observed by syncytium formation and by the detection of immunofluorescence antigens
using patients' antisera (9) and by mAb VAK-4 directed to p24 gag protein (10).
Furthermore, a release of HIV virus in culture media after established infection was
confirmed by the activity of reverse transcriptase.
mAbs and the Structures Defined by These Antibodies.
￿
Seven types of anticarbohydrate
mAbs were used for immunofluorescence and cytofluorometric analysis. The structures
defined by these antibodies and their origin are described in Table I. The antibody FH-
2 is directed to Le", ACFH-18 is directed to a long type 2 chain fucosylated structure
showing strong reactivity with trifucosyl Le' (trimeric Le') (11), the antibody FH-6 is
mA1, Structure defined Reference
FH2(IgM) Galol-+461 cNAcOl-3Galol-r4GIcRl-rFGIcNAc#l-3Galol-4GIc--+Cer 11
3
T
Fu cal
ACFH 18 Galol-461 cNAc0l-+3Galpl-4GI c N AcOl-+36A]01-461 cN Acp1-3Gal0l-,4Glc0l-l Cer I 1
(IgM) 3 3 3
T T T
Fu cal Fu cal Focal
FI16(IgM) NcuAca2~3Galfl~4GlcNAcfll~3Ga]t01~4GIcNAcB1~3Galt$1-r4GIcO1~lCer 12
3 3
T T
Fuca] Fu c al
6H-I (IgM) Galpl~4GI cNAc,B1~3Galp1~4GI cNAcol~3Galo1~4Glcp1~1Cer 13
2 3 3
T T T
Fura 1 Focal Focal
BM-I$(IgM) Focal-2Ga1141-4GIcNAco1--s3Gal#l-4GIc,61 -1Cer 14
3
T
Fu ca I
(:L'-1 (Ig(;3) GaINAcal~O-Ser/orThr Takahashi, H., and
anti=l-n Hakomori, S., un-
published data
11 H8 (Ig("s) Gal#1~3GANAca I~3GalO1~R Clausen, H., and Hak-
Anti-T 3 omori. S., unpub-ADACHI ET AL.
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directed to sialyl Le' carried by a long type 2 chain with internal fucosylation (12), and
KH-1 reacts specifically with trifucosyl Lef' (13). The antibody BM-1 is a subdone of AH-
6 directed to Le` structure as previously described (14). The antibody CU- I is directed to
Tn antigen (Takahashi, H., and S. Hakomori, unpublished observations), and HH-8 is
directed to Gal(31--+3GANAca residue of galactosyl A and is similar to T antigen associated
with glycoprotein (Clausen, H., and S. Hakomori, unpublished data).
Cytofuorometric Analysis of Membrane Antigen.
￿
A cell suspension of 5 x 105 H-9 or
TALL-1 cellswas mixed with 100 I1 of purified mAbs, reacted at 4°C for 60 min, washed
twice with RPMI 1640 medium, and subsequently added with 100 Al of 35 times-diluted
FITC-conjugated goat F(ab)2 fragment directed to anti-mouse IgM (No. 4352; Tago Inc.,
Burlingame, CA) or IgG (No. 4350 ; Tago Inc.). After reaction at 4°C for 30 min, cells
were washed twice with RPMI medium and fixed with 1 .5% formalin-PBS. A purified
mouse IgM (Coulter Electronics, Hialeah, FL) was used instead of primary antibody for a
control. Cytofluorometry was performed using an EPICS-C (Coulter Electronics). The
details of the conditions are described in the legend for Fig. 1 .
Immunofuorescence and Two-Color Cytofuorometric Analysis of Lymphocytes from HIV-
infected Patients. 10 ml of heparinized peripheral blood drawn from a vein of HIV-
infected patients was mixed with I ml of KAC-2'" (5% iron silicate sol; Japan Immuno-
research Laboratories, Takasaki, Japan) and maintained at 37'C for 1 h to eliminate
phagocytotic cells. The KAC-2-treated blood was then subjected to Ficol-Hypaque gra-
dient centrifugation to obtain mononuclear cell fraction free from granulocytes and
monocytes. Aliquots of the lymphocyte suspension were stained by immunofluorescence
with various mAbs as described above', and examined by fluorescence microscopy. Aliquots
of cells were washed with PBS containing 0.1% gelatin and 0.1% sodium azide. BM-I
antibody was added and incubated for 60 min at 4°C, followed by washing with PBS-
gelatin. FITC-labeled anti-mouse IgM (F[ab]2 fragment, purchased from Tago Inc.) was
then added and incubated for 30 min at 4°C followed by washing with PBS-gelatin.
Subsequently, phycoerythrin coupled to CD3, CD4, or CD8 antibody (Becton Dickinson
& Co., Oxnard, CA) was added and incubated for 30 min at 4° C, washed with PBS, fixed
with 1 .5% formalin for 15 min at 4 °C, washed and resuspended in PBS, and analyzed by
cytofluorometry (FACS-3). The ratio of CD4/CD8 was determined by analysis with
phycoerythrin-labeled CD4 and CD8 by the procedure described above.
Results
Both H-9 and TALL- I cells were essentially negative with immunofluorescence
staining and cytofluorometric assay with seven anticarbohydrate antibodies, as
listed in Table 1 . In striking contrast, both H-9 and TALL-1 cells after infection
with HIV became strongly positive with antibody BM-1 after infection; the
expression of the BM-1-defined antigen was found subsequent to the appearance
of the HIV-specific gag p24 protein antigen defined by mAb VAK-4, as well as
by antibodies in the patients' sera (Fig. 1). The cytofluorometric pattern with
BM-1 antibody is shown in Fig. 2, and the percent of positive cells, defined by
various antibodies, before and after infection with HIV virus, is shown in Fig. 3 .
All these infected cells were characterized by the presence of positive reaction
with mAbs directed to HIV gag protein p24 and by syncytium formation.
The lymphocyte fractions of 17 HIV-infected patients were prepared, and
their reactivity with BM-I mAb was observed under immunofluorescence. Lym-
phocytes from AIDS patients showed a strong immunofluorescence with BM-1,
and those from ARC patients showed positive staining also, but with less fre-
quency as compared with lymphocytes from the AIDS patients (Fig. 4). With
hematoxylin and eosin staining of these BM-1 + cells, their morphology was
distinctively different from monocytes but was characteristic of lymphoid cells.326
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FIGURE 1 . Time-dependent changes in Ley
antigen and HIV-associated antigens expressed
in human T cell leukemia cell line TALL-1 .
TALL-I cells in culture were infected by the
addition of supernatant from HIV-infected
TALL-1 culture, which contained reverse tran-
scriptase activity with 58,000 cpm/ml at the
1st, 3rd, and 6th days (arrow), and subse-
quently, expression of HIV-associated antigen
in cells was determined by indirect immuno-
fluorometry using anti-p24 mAb and by serum
of an AIDS patient . Simultaneously, the expres-
sion of Ley antigen was monitored by cytofluo-
rometry with mAb BM-I . Expression of anti-
gens is shown by the ratio of positive cells in
percent . (0) Reactivity with BM-1 ; (O) reactivity
with patient's serum ; (a) reactivity with anti-
p24 .
FIGURE 2 . Cytofluorometric pattern of expression of
Ley antigen in human T cell leukemia cells H-9 and
TALL-1 before and after infection with HIV . (la, lb, Ila,
and IIb) H-9 cells; (Illa, IIIb, IVa, and IVb) TALL- I cells.
(]a) control H-9 cells (uninfected) treated with mouse
IgM ; (Ib) H-9 cells infected withHIV treated with mouse
IgM ; (Ila) H-9 cells uninfected and treated with mAb
BM-I ; (IIb) H-9 cells infected with HIV treated with mAb
BM-1 . (IIIa) control uninfected TALL-1 cells treated with
mouse IgM ; (IIIb) TALL-1 cells infected with HIV
treated with mouse IgM ; (IVa) uninfected TALL-I cells
treated with mAb BM-1 ; (IVb) TALL- I cells infected with
HIV treated with mAb BM-1 .
FIGURE 3 .
￿
Comparative reactivities of human T leuke-
mia cells with various anticarbohydrate antibodies . (Solid
bar) before infection ; (hatched bar) after infection with
HIV . The top panel shows reactivity of TALLA cells ;
the bottom panel shows reactivity of H-9 cells . Antibodies
tested for reactivity are identified at the abscissa . The
structures defined by these antibodies are shown in "Table
I . The results from TALL-I cell line are determined at
the 20th day after infection .
Furthermore, monocytes were eliminated by KAC-2 treatment . These BM-1 +
cells were characterized as being CD3+ , as indicated by dual staining (see below),
and therefore are considered to be T cells . In addition, those cells showing
strongly positive reactivity with BM-1 as well as CD3 antibody were characterizedADACHI ET AL .
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Incidence of BM-1'cells in CD3' population in
AIDS patients and its correlation with the size of the CD4'
population (CD4'/CD8' ratio). Incidence of BM-1' cells in
CD3' population and the ratio of CD4'/CD8' populations
were analyzed by two-colorcytofluorometry, as describedin
the text. Note that BM-1 expression tends to increase when
the CD4' population decreases on progression of AIDS.
Normal subjects have a CD4'/CD8' ratioof -1.8, and BM-
I expression is <I%.
by granular structures in the cytoplasm, and therefore, are considered to be
granular lymphocytes, particularly at blast stage. None of the carbohydrate
antigens defined by these seven mAbs were found to be expressed in normal
lymphocytes, except the antigen defined by FH-6, which reacts with an unknown
population of human lymphocytes (data not shown). Two-color cytofluorometry
ofperipheral blood lymphocytes of HIV-infected patients with a combination of
BM-1 and CD3 antibodies clearly indicates that BM-1 + cells are a T lymphocyte
population. Incidence of the BM-1 + population in the CD3' population increased
greatly when the CD4+ population decreased greatly in AIDS patients, as
characteristically indicated by the lower ratio of CD4+/CD8+ in advanced stages
of the disease (Fig. 5). The clinical stage of symptoms in AIDS patients correlates
well with the CD4+/CD8+ ratio. In normal subjects, in which the CD4'''/CD8+
ratio is -1 .8, the incidence of BM-1 reactivity among CD3'' lymphocytes (mature
T cells) is very low (see legend for Fig. 5).
Discussion
The results of this study clearly indicate a dramatic change in expression of
Ley antigen in human T cell lines infected with HIV, as well as in peripheral T
lymphocytes of HIV-infected patients. Six other carbohydrate antigens defined
by respective mAbs did not show significant differences between infected and
noninfected cells. Two-colorcytofluorometric analysis ofthe lymphocyte fraction
of 17 HIV-infected patients indicates that Ley expressors are within the CD3''
population and that there is a large degree of variation in Ley expression in
CD3+ population among HIV-infected patients. The morphology of the BM-1 +
cells was distinct from monocytes but characteristic of lymphocytes. Some pop-
ulations showing strong expression of Ley and CD3 have been characterized by
granular structures in the cytoplasm and are considered to be granular lympho-
cytes. The incidence of Ley expression in the T cell population in AIDS and
ARC patients was much higher than the incidence of expression of the viral
antigen. This situation is different from HIV-infected T cell lines in vitro, inADACHI ET AL.
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which Le}' expression paralleled viral antigen expression. The reason for this
discrepancy is unknown at this time . It is possible that Ley is expressed at the
very early stage of viral infection and that the expression can be induced by
other in vivo factors, such as cellular interactions. Nevertheless, the incidence of
Ley expression increased progressively in patients with advanced stages of AIDS,
in which the CD4+ population greatly decreased. A progressive increase in the
incidence of Ley expression in the CD3+ population associated with clinical stages
of AIDS was of particular importance, e.g., 8.6% in Center for Disease Control
(CDC) classification II, 10.1% in CDC classification III, and 19 .3% in CDC
classification IV . Human T cells infected with HIV were characterized by
syncytium formation and the presence of HIV gag protein antigen (p24).
The change of glycosylation pattern in Herpes virus-infected cells has been
described (15, 16) although the extent of changes is less pronounced than in
glycosylation associated with oncogenic transformation (17). A striking appear-
ance of Ley antigen in HIV-infected cells and in lymphocytes of patients with
AIDS and ARC is therefore a peculiar phenomenon indicating the possibility
that HIV infection alters the membrane phenotype of T cells, remarkably similar
to the alteration observed in cells oncogenically transformed by tumor viruses.
Since no changes of Le' determinant or sialyl Le'° determinant defined by FH-2
or FH-6 were observed in HIV-infected cells, the appearance of Ley determinant
defined by BM-1 may not be associated with induced fucosylation of preexisting
Le' determinant. The entire process of glycosylation, including the extension of
type 2 chain coupled with terminal and subterminal fucosylation, is induced in
HIV-infected T cells as well as T lymphocytes of AIDS and ARC. Interestingly,
cell growth of HIV-infected cells was strongly inhibited or cytolysis was induced
in the presence of BM-1 antibody and human serum complement, and nonin-
fected cells were not affected by BM-1 antibody and complement (Adachi, M.,
N. Kashiwagi, and S. Hakamori, unpublished data). Ley antigen defined by BM-
1 antibody was not detectable in virions of HIV as determined by competitive
RIA and Western blotting (data not shown) . Therefore, the expression of Ley
antigen in HIV-infected cells is obviously a virus-dependent induction of glyco-
sylation changes in host cells. In previous studies it was demonstrated that T cell
leukemia cells showed significant changes in glycosylation pattern (18, 19) in
particular, the appearance of GDs in adult T cell leukemia was noticeable (20),
while T lymphocytes infected with HIV have now been characterized by a
remarkable expression of Ley, although the phenotype changes induced by HIV
are strikingly different; i.e., clear reduction of cell growth, anisocytosis, and
syncytium formation. It is of great interest to determine whether Ley determi-
nant, highly expressed in HIV-infected cells, may have some role in the altered
phenotype of the CD3+ cell subpopulation .
Summary
Ley determinant (Fuca1--~,2GA,O1-*4[Fucal-a3]GlcNAcO1--*R) defined by
mAb BM-I is highly expressed in human immunodeficiency virus (HIV)-infected
T cell lines and in CD3+ peripheral mature T cells of patients with acquired
immune deficiency syndrome (AIDS) or with AIDS-related complex (ARC). Ley
expression increased greatly in the CD3+ population in the advanced stage of330
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AIDS when the CD4+ population decreased greatly. Six other carbohydrate
antigens tested by their respective mAbs were not detected in these same cells.
None of the carbohydrate antigens tested by the seven mAbs used in this study
were found in noninfected T cell lines and in normal peripheral blood lympho-
cytes.
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